Adverse Events Disclosures May Increase After Supreme Court Ruling Against Matrixx, But "Total Mix" Matters
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies may have to disclose adverse event reports that are not statistically significant, but the court says the amount of disclosure needed can be limited by how much a company tells the market about an issue in general.
You may also be interested in...
Judge Gorsuch Could Be Pharma Ally In FDA Disputes
Supreme Court nominee's opposition to deference for administrative agencies could help biopharma industry in its battle over off-label communications if the issue ever goes before the court; he also supports securities litigation reform.
Pharma Securities Fraud Worries Reduced By Supreme Court Case
High court finds that a corporation’s statement of opinion is not actionable unless company did not sincerely believe it; ruling makes it harder for plaintiffs to file stock fraud claims.
Takeda False Claim Act Case May Allow Supreme Court To Set Evidence Threshold
High court seeks Solicitor General’s views on whether a whistleblower must identify a specific false claim submitted to the government or just have evidence to infer the submission; Solicitor General has previously supported latter position.